1. Home
  2. CDXS

as 10-17-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Industrials

Major Chemicals

Nasdaq

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Founded: 2002 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 216.6M IPO Year: 2010
Target Price: $11.00 AVG Volume (30 days): 542.5K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.81 EPS Growth: N/A
52 Week Low/High: $1.90 - $6.08 Next Earning Date: 10-30-2025
Revenue: $57,164,000 Revenue Growth: -6.12%
Revenue Growth (this year): 12.88% Revenue Growth (next year): 21.64%

CDXS Daily Stock ML Predictions

Stock Insider Trading Activity of Codexis Inc. (CDXS)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Erbez Georgia CDXS Chief Financial Officer Oct 13 '25 Sell $2.51 6,239 $15,628.70 70,636
MOORE ALISON CDXS Chief Technical Officer Oct 13 '25 Sell $2.51 6,239 $15,629.32 169,332

Share on Social Networks: